Ultragenyx Pharmaceutical Inc.’s Price-to-Earnings Ratio at a glance
Ultragenyx Pharmaceutical Inc. reports price-to-earnings ratio of -6.7x for Dec 2024. The prior period recorded -5.8x (Dec 2023). Year over year the metric moved −0.89 (−15.4%). The rolling three-period average stands at -5.7x. Data last refreshed Dec 7, 2025, 2:53 AM.
Latest reading
-6.7x · Dec 2024
YoY movement
−0.89 (−15.4%)
Rolling average
-5.7x
Current Price-to-Earnings Ratio
-6.7x
−0.89
−15.4%
Rolling average
-5.7x
Latest Value
-6.7x
Dec 2024
YoY Change
−0.89
Absolute
YoY Change %
−15.4%
Rate of change
3-Period Avg
-5.7x
Smoothed
Narrative signal
Ultragenyx Pharmaceutical Inc.’s price-to-earnings ratio stands at -6.7x for Dec 2024. Year-over-year, the metric shifted by −0.89, translating into a −15.4% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-earnings ratio shapes Ultragenyx Pharmaceutical Inc.'s story
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports price-to-earnings ratio of -6.7x. Analyze price-to-earnings history, valuation swings, and relative multiples to benchmark market expectations.
Why the P/E ratio matters
The price-to-earnings multiple reveals how much investors are willing to pay for each dollar of net income. Elevated P/E levels suggest strong growth expectations or limited earnings.
Tracking valuation cycles
Monitoring multi-year P/E trends highlights how macro cycles, product launches, or profitability changes impact valuation over time.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
86.3%
Operating Margin
-95.7%
Net Profit Margin
-101.6%
Return on Equity
-222.9%
Return on Assets
-37.9%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Ultragenyx Pharmaceutical Inc. (RARE) FAQs
Answers tailored to Ultragenyx Pharmaceutical Inc.’s price-to-earnings ratio profile using the latest Financial Modeling Prep data.
What is Ultragenyx Pharmaceutical Inc.'s current price-to-earnings ratio?
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports price-to-earnings ratio of -6.7x. This reading reflects the latest filings and price data for RARE.
How is Ultragenyx Pharmaceutical Inc.'s price-to-earnings ratio trending year over year?
Year-over-year, the figure shifts by −0.89 (−15.4%). Pair this context with revenue growth and free cash flow signals to gauge momentum for RARE.
Why does price-to-earnings ratio matter for Ultragenyx Pharmaceutical Inc.?
The P/E ratio compares a company’s share price with its per-share earnings to gauge valuation. For Ultragenyx Pharmaceutical Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Ultragenyx Pharmaceutical Inc.'s price-to-earnings ratio above its recent average?
Ultragenyx Pharmaceutical Inc.'s rolling three-period average sits at -5.7x. Comparing the latest reading of -6.7x to that baseline highlights whether momentum is building or fading for RARE.
How frequently is Ultragenyx Pharmaceutical Inc.'s price-to-earnings ratio refreshed?
Data for RARE was last refreshed on Dec 7, 2025, 2:53 AM and updates automatically every 24 hours, keeping your valuation inputs current.